Trisomy 21 in acute myeloid leukemia

Cancer Genetics and Cytogenetics
C H WeiP M Chen

Abstract

We report two cases of acute myeloid leukemia (AML), constitutionally normal, with trisomy 21. Trisomy 21 does not often occur as a sole numerical karyotypic abnormality in AML leukemia. The possible prognostic significance of the finding in acute leukemia is discussed.

References

Aug 1, 1992·Leukemia & Lymphoma·R C RibeiroC H Pui
Mar 1, 1991·Cancer Genetics and Cytogenetics·T KnutsenP K Martin
Jun 1, 1986·Cancer Genetics and Cytogenetics·S Heim, F Mitelman

❮ Previous
Next ❯

Citations

Nov 7, 2000·Cancer Genetics and Cytogenetics·L RobinsonA Smith
May 10, 2001·Cancer Genetics and Cytogenetics·B RolandA Pinto
Jul 21, 2001·Cancer Genetics and Cytogenetics·T OdagakiK Saigo
Apr 12, 2002·Cancer Genetics and Cytogenetics·Katsuya YamamotoHiroyuki Hamaguchi
Jun 1, 1997·Cancer Genetics and Cytogenetics·M GallegoS Woessner
Feb 13, 2001·Cancer Genetics and Cytogenetics·C MorerioC Panarello
Aug 4, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Meng-Ju LiDong-Tsamn Lin
Jan 14, 2009·American Journal of Hematology·Yizhi ChengJie Jin
Nov 6, 2004·Cancer Genetics and Cytogenetics·Mitsuru YoshimotoMasayuki Tsujisaki
Nov 3, 2009·Journal of Zhejiang University. Science. B·Hua-feng WangJie Jin
Aug 24, 2013·Clinical Lymphoma, Myeloma & Leukemia·Paolo StratiJorge Cortes
Feb 12, 2019·Current Treatment Options in Oncology·Yahya DaneshbodDaniel A Arber
Dec 22, 2005·American Journal of Hematology·Lou YinjunChen Zhimei
Aug 26, 2006·Stem Cells·David Dingli, Franziska Michor
Oct 24, 2017·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Lin WangYi-Ning Qiu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.